UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Common stock, without par value CTS New York Stock Exchange FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------|-------|------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-4639 CTS CORPORATION (Exact name of registrant as specified in its charter) Indiana 35-0225010 (State or other juris ...

Financial Data and Key Metrics Changes - Fourth quarter sales were $123 million, up 7% compared to the same period in 2019 and up 8% sequentially [3][27] - Full year sales were $424 million, down 10% from $469 million in 2019 due to the pandemic [4][28] - Fourth quarter gross margin increased by 110 basis points to 34.7% from the same period last year [4][27] - EBITDA margin for the fourth quarter was 21.4%, up from 20.3% in Q4 2019 [4] - Adjusted earnings per share for the fourth quarter were $0.43, up 16% from $0.37 in Q4 2019 [4][28] - Full year adjusted earnings per share were $1.12, down from $1.45 last year [4][31] Business Line Data and Key Metrics Changes - Sales to transportation customers increased by 12% year-over-year in Q4 [27] - Sales to other end markets were flat year-over-year, with industrial and defense markets showing double-digit growth [27][29] - Medical end market sales were down 7% for the full year, continuing to show softness [29] Market Data and Key Metrics Changes - U.S. light-vehicle transportation market volume is expected to improve in the 14 million to 16 million unit range [21] - European sales are forecasted in the 18 million to 19 million unit level, with some uncertainty due to recent lockdowns [22] - The Chinese market is expected to remain solid, with volumes in the 24 million to 26 million unit range [22] Company Strategy and Development Direction - The company is focused on returning to growth and leveraging the recent acquisition of Sensor Scientific [8][10] - The 2025 Initiative emphasizes annualized profitable growth, stronger customer relationships, and enhancing operational capabilities [26] - The company aims to build a robust M&A pipeline despite challenges posed by COVID-19 [18] Management's Comments on Operating Environment and Future Outlook - Management remains cautious entering 2021 due to potential pandemic disruptions and semiconductor shortages [7][20] - The company expects sales for 2021 to be in the range of $430 million to $490 million, with adjusted earnings expected between $1.20 and $1.60 [24] - Management is monitoring the impact of COVID-19 and supply chain disruptions closely [25] Other Important Information - The acquisition of Sensor Scientific is expected to add approximately $6 million in annualized revenue [10] - The company reduced its long-term debt balance to $55 million from $106 million at the end of Q3 2020 [34] - The company finished 2020 with a healthy balance sheet and strong liquidity position [33] Q&A Session Summary Question: Can you provide guidance on 2021 revenue and earnings cadence? - Management indicated that while they cannot provide quarterly specifics, they are concerned about potential pandemic disruptions and semiconductor shortages impacting the automotive market [38][39] Question: What is the order momentum heading into the March quarter? - Management noted that new business wins were softer than usual, with several OEMs delaying decisions, but they are optimistic about a good start in January [44][45] Question: How are pricing and volume commitments being affected by supply chain dynamics? - Management stated that they have not seen significant ASP erosion and have raised prices in response to supply chain tightness [50][51] Question: What is the expected impact of commodity pricing and currency on gross margins? - Management expects a 100 basis point unfavorable impact from currency and is working to manage commodity pricing effects [52][54] Question: What is the company's exposure to electric vehicles (EV)? - Management indicated that their exposure to products affected by the transition to EVs is very low, with expectations of compensation by 2021/2022 [63] Question: What is the outlook for the medical market in the second half of 2021? - Management anticipates a gradual flattening of softness in the medical market in the second half of the year [65]

Investor Presentation January 2021 Forward Looking Statements This presentation contains statements that are, or may be deemed to be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, any financial or other guidance, statements that reflect our current expectations concerning future results and events, and any other statements that are not based solely on historical fact. Forward-looking st ...

CTS Corporation (NYSE:CTS) Q3 2020 Earnings Conference Call October 29, 2020 10:00 PM ET Company Participants Kieran O'Sullivan - President, Chief Executive Officer and Chairman of the Board Ashish Agrawal - Vice President and Chief Financial Officer Conference Call Participants Karl Ackerman - Cowen Justin Long - Stephens John Franzreb - Sidoti Hendi Susanto - G. Research Operator Good day, and welcome to the CTS Corporation Third Quarter 2020 Earnings Call. [Operator Instructions] Today's conference i ...

Financial Performance - Q3 YTD 2020 net sales were $301 million[3], compared to $469 million in 2019[20] - Adjusted gross margin was 32% of sales for Q3 YTD 2020[39] - Adjusted EBITDA was 17% of sales for Q3 YTD 2020[39] - Adjusted diluted EPS was $0.69 for Q3 YTD 2020[39] - Total debt to capitalization was 20.4% as of Q3 2020[50] Market and Strategy - The company aims to be a leading provider of sensing and motion devices and connectivity components[2] - Transportation end market accounts for 56% of sales[3] - Industrial end market accounts for 21% of sales[3] - Aero & Defense end market accounts for 9% of sales[3] - Medical end market accounts for 11% of sales[3] - Telecom & IT end market accounts for 3% of sales[3]

Table of Contents Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, without par value CTS New York Stock Exchange UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______________ to _______________ Commission File Number: 1-4639 CTS CORPORATION (Exact name of registrant as specified in its charter) IN 35-0225010 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______________ to _______________ Commission File Number: 1-4639 CTS CORPORATION (Exact name of registrant as specified in its charter) IN 35-0225010 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-4639 CTS CORPORATION (Exact name of registrant as specified in its charter) Indiana 35-0225010 (State or other jurisdiction of incorpo ...